Individualization in Treating Type 2 Diabetes

Amy Butts, PA-C, MPAS, CDE, BC-ADM

Individualization to care in patients with diabetes is important. No two patients have the same medical history. Glycemic targets will vary from patient to patient. The American Diabetes Association recommends an A1C of less than 7%. However, the duration of disease, hypoglycemia risk, and other comorbidities play a large role in selecting the glycemic target for the individual patient. For example, a patient with diabetes who has had the disease for 25 years, has chronic renal failure, and has hypoglycemia unawareness may be better to have an A1C target of less than 8% to avoid hypoglycemia risk but still prevent worsening of complications.
Individualization is also important when choosing pharmacologic agents for the treatment of type 2 diabetes. After lifestyle and metformin, it is now encouraged that we assess the patient and their medical history when choosing what second-line agent is best for the patient. Factors like established CVD, chronic diabetic kidney disease, heart failure, and hypoglycemia risk are some variables that should be considered when choosing the right medication for the patient.
One size does not fit all and we as providers need to stay updated on the new recommendations on treatment options for our patients with type 2 diabetes.

 

See Amy Butts, PA-C, MPAS, CDE, BC-ADM speak at the GAPA 2020 Summer Conference in Sandestin, Florida July 13-17.

Share this story:

Share on Facebook Share on Twitter Share on LinkedIn Email to a Friend
GAPA